|drug3728||Standard of Care Wiki||0.16|
|D058186||Acute Kidney Injury NIH||0.19|
|D014947||Wounds and Injuries NIH||0.17|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Our overarching goal is to improve the outcomes of critically ill COVID-19 patients with or at risk for development of acute kidney injury (AKI). The objective of this study is to determine the role of a protocol to manage urine alkalization using a simple medication that has been used for a very long time, is safe, and without significant side-effects. We aim to determine the feasibility and safety of a urine alkalinization protocol for the prevention of AKI in patients testing positive for COVID-19.
Description: Primary feasibility outcome will be the proportion of patients treated who achieve >50% of urine measurements pH ≥= 7.2 over the duration of treatment.Measure: pH Time: 10 days
Description: Primary efficacy outcome will be the number of days alive and free of stage 2-3 AKI (up to 28) in each group.Measure: Number of Days Alive Free of Stage 2-3 AKI Time: 28 days post-treatment
Description: proportion of patients developing stage 2-3 AKI (or stage 3 if already at stage 2 at enrollment).Measure: Stage 2-3 AKI Time: 28 days
Description: Ventilator-free days to 28 daysMeasure: Vent-Free Time: 28 days
Description: Hospital-free days to 60 daysMeasure: Hospital-Free Time: 60 days post-index hospitalization
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports